- In January 2025, South Korea's SK bioscience and global healthcare leader Sanofi announced an enhanced partnership aimed at targeting the preventive medicine market both in Korea and internationally. SK bioscience has entered into a co-promotion and distribution agreement with Sanofi Korea for the respiratory syncytial virus (RSV) preventive antibody injection, Beyfortus, and the hepatitis A vaccine, Avaxim
- In September 2024, Indian Immunologicals Limited (IIL), based in Hyderabad, announced the launch of the pediatric dose of Havisure (0.5 ml), India’s first locally developed Hepatitis A vaccine. The company highlighted that this launch represents a key milestone in IIL’s continued dedication to offering affordable and effective vaccines, with a particular focus on protecting vulnerable groups, especially children
- In April 2023, Sanofi introduced AVAXIM Junior in the UK, an inactivated hepatitis A vaccine designed for children aged 12 months to 15 years to help prevent hepatitis A virus infection. The vaccination schedule involves two doses administered via intramuscular injection, with a recommended interval of 6 to 36 months, though the doses can be given up to 7 years apart
- In January 2023, Sinovac Biotech Ltd., a prominent biopharmaceutical provider in China, announced that its inactivated hepatitis A vaccine, Healive, received approval from the Lebanese Ministry of Public Health (MOPH) for use in children aged 1 to 16 years
